Skip to Content
Merck
All Photos(2)

Documents

I1877

Sigma-Aldrich

Isocitric Dehydrogenase (NADP) from porcine heart

Type I, 0.5-3.0 unit/mg solid (plus numerous enzyme activities associated with porcine heart)

Synonym(s):

threo-Ds-Isocitrate: NADP+ oxidoreductase, ICDH, IDH

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

CAS Number:
9028-48-2
Enzyme Commission number:
1.1.1.42 (BRENDA, IUBMB)
EC Number:
232-835-3
MDL number:
MFCD00131420
UNSPSC Code:
12352204
NACRES:
NA.54

biological source

Porcine heart

type

Type I

form

solid

specific activity

0.5-3.0 unit/mg solid (plus numerous enzyme activities associated with porcine heart)

storage temp.

−20°C

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Isocitrate dehydrogenase (IDH) plays a major role in the Krebs cycle by catalyzing the oxidative decarboxylation of isocitrate. The oxidative decarboxylation of isocitrate generates α-ketoglutarate and NADPH. NADPH produced is essential for the production of fatty acids and cholesterol. This NADP-dependent molecules serves as homodimers.

Quality

Crude

Unit Definition

One unit will convert 1.0 μmole of isocitrate to α-ketoglutarate per min at pH 7.4 at 37°C.

Pictograms

Health hazard
GHS08

Signal Word

Danger

Hazard Statements

H334

Precautionary Statements

P261 - P284 - P501

Hazard Classifications

Resp. Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The Molecular Pathogenesis of Glioblastoma
Glioblastoma, 21-31 (2016)
Molecular Testing for Glioblastoma
Diagnostic Molecular Pathology, 339-347 (2017)
Chapter One - Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression
Ntziachristos P, et al.
Advances in Immunology, 117, 1-38 (2013)
Omar Abdel-Wahab et al.
Hematology. American Society of Hematology. Education Program, 2012, 56-64 (2012-12-13)
The myelodysplastic syndromes (MDS) are a clinically and cytogenetically heterogeneous group of clonal diseases characterized by ineffective hematopoiesis, peripheral blood cytopenias, and an increased risk of progression to acute myeloid leukemia. The precise molecular mechanisms behind the development of MDS
Maria Paola Martelli et al.
Blood reviews, 27(1), 13-22 (2012-12-25)
Acute myeloid leukemia (AML) is a molecularly heterogeneous disease. Based on cytogenetics and FISH, AML patients are stratified into three major risk categories: favourable, intermediate and unfavourable. However, prognostic stratification and treatment decision for the intermediate risk category, that mostly
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service